Core Viewpoint - Kangyuan Pharmaceutical has recently received a drug registration certificate for Xiebaisan Granules from the National Medical Products Administration [2] Company Summary - Kangyuan Pharmaceutical announced the receipt of the drug registration certificate for Xiebaisan Granules on December 12 [2]

Core Viewpoint - Kangyuan Pharmaceutical (600557) has recently received a drug registration certificate for Xiebaisan granules from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product aimed at treating pediatric cough and asthma due to lung heat [1] Group 1 - The drug Xiebaisan is indicated for clearing lung heat and alleviating cough and asthma symptoms in children [1] - The approval of the drug registration certificate represents a milestone for Kangyuan Pharmaceutical, potentially enhancing its product portfolio and market presence [1]

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) has received the drug registration certificate for Xiebaisan Granules from the National Medical Products Administration, which is expected to enhance the clinical application of traditional Chinese medicine and improve the company's market competitiveness in pediatric medication [1] Group 1: Product Approval - The drug's generic name is Xiebaisan Granules, with registration standard number YBZ00832025 and approval number Guoyao Zhunzi C20250016 [1] - Xiebaisan is effective in clearing lung heat and alleviating cough and asthma, specifically for pediatric patients with symptoms such as wheezing and cough [1] Group 2: Clinical Application - Xiebaisan has a long history of clinical use and is recognized for its efficacy and low adverse reactions, which supports its broader application in clinical settings [1] - The approval of Xiebaisan Granules is expected to promote the use of classical formulas in clinical practice, enhancing the level of traditional Chinese medicine services [1] Group 3: Market Impact - Pediatric medication is a key area for the company, and the approval of Xiebaisan Granules enriches its pediatric product lineup [1] - This development is anticipated to strengthen the company's market competitiveness and brand influence in the pediatric sector, laying a solid foundation for sustained profitability [1]

Core Viewpoint - Kangyuan Pharmaceutical has received a drug registration certificate for Xiebaisan Granules from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1: Product Details - The drug's generic name is Xiebaisan Granules, with main ingredients including fried mulberry bark, prepared lycium bark, fried licorice, and glutinous rice [1] - The dosage form is granules, with a specification equivalent to 8.20g of decoction pieces per bag [1] - The registration classification is Traditional Chinese Medicine Class 3.1, and the drug has a shelf life of 18 months, classified as a prescription drug [1]